Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Single‐dose immunisation with a multimerised SARS‐CoV‐2 receptor binding domain (RBD) induces an enhanced and protective response in mice
Ralf Salzer, Jordan J. Clark, Marina Vaysburd, et al.
FEBS Letters (2021) Vol. 595, Iss. 18, pp. 2323-2340
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Neuroinvasion and Neurotropism by SARS-CoV-2 Variants in the K18-hACE2 Mouse
Frauke Seehusen, Jordan J. Clark, Parul Sharma, et al.
Viruses (2022) Vol. 14, Iss. 5, pp. 1020-1020
Open Access | Times Cited: 93
Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals
David A. Meekins, Natasha N. Gaudreault, Jüergen A. Richt
Viruses (2021) Vol. 13, Iss. 10, pp. 1993-1993
Open Access | Times Cited: 93
Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform
Christopher Chevillard, Axelle Amen, Solène Besson, et al.
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1913-1925
Open Access | Times Cited: 28
Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2
Chulwoo Kim, Jae-Deog Kim, Sang‐Uk Seo
The Journal of Microbiology (2022) Vol. 60, Iss. 3, pp. 335-346
Open Access | Times Cited: 28
Therapeutic Protein-Based Vaccines
Shaban Ahmad, Vandana Dahiya, Arpana Vibhuti, et al.
(2023), pp. 355-384
Closed Access | Times Cited: 16
A Multi-Disulfide Receptor-Binding Domain (RBD) of the SARS-CoV-2 Spike Protein Expressed in E. coli Using a SEP-Tag Produces Antisera Interacting with the Mammalian Cell Expressed Spike (S1) Protein
Subbaian Brindha, Yutaka Kuroda
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1703-1703
Open Access | Times Cited: 23
Protein-based nano-vaccines against SARS-CoV-2: Current design strategies and advances of candidate vaccines
Dongliang Wang, Youqing Yuan, Bin Liu, et al.
International Journal of Biological Macromolecules (2023) Vol. 236, pp. 123979-123979
Open Access | Times Cited: 14
Ferritin-based nanomedicine for disease treatment
Yuanjun Zhu, Yuefeng Zhu, Tianmiao Cao, et al.
Medical Review (2023) Vol. 3, Iss. 1, pp. 49-74
Open Access | Times Cited: 12
Protein-based Nanoparticle Vaccine Approaches Against Infectious Diseases
Daniel Tapia, Arturo Reyes‐Sandoval, Javier I. Sanchez-Villamil
Archives of Medical Research (2023) Vol. 54, Iss. 3, pp. 168-175
Closed Access | Times Cited: 10
Ferritin nanocages as efficient nanocarriers and promising platforms for COVID-19 and other vaccines development
Aliaksandra A. Reutovich, Ayush Srivastava, Paolo Arosio, et al.
Biochimica et Biophysica Acta (BBA) - General Subjects (2022) Vol. 1867, Iss. 3, pp. 130288-130288
Open Access | Times Cited: 18
A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice
Lorena M. Coria, Lucas M. Saposnik, Celeste Pueblas Castro, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 17
A modular and self-adjuvanted multivalent vaccine platform based on porcine circovirus virus-like nanoparticles
Zehui Liu, Zhuofan Deng, Ying Lu, et al.
Journal of Nanobiotechnology (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 16
The Stereotypic Response of the Pulmonary Vasculature to Respiratory Viral Infections: Findings in Mouse Models of SARS-CoV-2, Influenza A and Gammaherpesvirus Infections
Simon De Neck, Rebekah Penrice-Randal, Jordan J. Clark, et al.
Viruses (2023) Vol. 15, Iss. 8, pp. 1637-1637
Open Access | Times Cited: 9
The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19
Rebekah Penrice-Randal, Eleanor G. Bentley, Parul Sharma, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Protein Nanoparticles as Vaccine Platforms for Human and Zoonotic Viruses
Kush Kumar Pandey, Bikash R. Sahoo, Asit K. Pattnaik
Viruses (2024) Vol. 16, Iss. 6, pp. 936-936
Open Access | Times Cited: 2
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case
Lee Tatham, Anja Kipar, Joanne Sharp, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 8
Open Access | Times Cited: 2
Protein-Based Nanoparticle Vaccines for SARS-CoV-2
Hyo-Dong Sung, Nayeon Kim, Yeram Lee, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13445-13445
Open Access | Times Cited: 18
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case
Lee Tatham, Anja Kipar, Joanne Sharp, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 12
The position of Spy Tag/Catcher system in hepatitis B core protein particles affects the immunogenicity and stability of the synthetic vaccine
Yanan Sheng, Zhengjun Li, Xuan Lin, et al.
Vaccine (2023) Vol. 41, Iss. 33, pp. 4867-4878
Closed Access | Times Cited: 6
Protein Nanoparticles as Viral Vaccine Platforms
Kush Kumar Pandey, Bikash R. Sahoo, Asit K. Pattnaik
(2024)
Open Access | Times Cited: 1
Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters
Megan Neary, Joanne Sharp, Eduardo Gallardo‐Toledo, et al.
Viruses (2023) Vol. 15, Iss. 8, pp. 1744-1744
Open Access | Times Cited: 4
Evaluation of intranasal nafamostat or camostat for SARS-CoV-2 chemoprophylaxis in Syrian golden hamsters
Megan Neary, Helen Box, Joanne Sharp, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 11
An Escherichia coli Expressed Multi-Disulfide Bonded SARS-CoV-2 RBD Shows Native-like Biophysical Properties and Elicits Neutralizing Antisera in a Mouse Model
Subbaian Brindha, Takahiro Yoshizue, Rawiwan Wongnak, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 15744-15744
Open Access | Times Cited: 6
Antisera Produced Using an E. coli-Expressed SARS-CoV-2 RBD and Complemented with a Minimal Dose of Mammalian-Cell-Expressed S1 Subunit of the Spike Protein Exhibits Improved Neutralization
Takahiro Yoshizue, Subbaian Brindha, Rawiwan Wongnak, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10583-10583
Open Access | Times Cited: 3
Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters
Eduardo Gallardo‐Toledo, Megan Neary, Joanne Sharp, et al.
Viruses (2023) Vol. 15, Iss. 11, pp. 2161-2161
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top